STAT+: Pharmalittle: We’re reading about upbeat results for a Duchenne drug, Takeda layoffs, and much more
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Biogen reported that its experimental Alzheimer’s drug diranersen lowered tau protein levels in spinal fluid and brain tissue of early‑stage patients.
- Biogen found that the tau reductions correlated with a measurable slowing of cognitive decline in the trial.
- Biogen noted that diranersen must be administered via a spinal injection, a delivery method that could limit its practicality.
Why it matters: Alzheimer’s patients gain a potential disease‑modifying option, while clinicians face the challenge of spinal‑injection logistics; Takeda’s job cuts will reduce its payroll by 4,500 positions, easing debt but risking morale.
Ask SkimNews
